A medical safety alert was issued last Wednesday by the Medicines and Healthcare Products Regulatory Agency concerning the ASV mode available in selected ResMed ventilators.
The alert urges caution among doctors currently treating patients with specific cardiac conditions with the ASV mode, saying: “Physicians should assess all patients currently being treated with ASV mode for symptomatic chronic heart failure and if necessary undertake an assessment of LVEF. Where appropriate discontinuation of treatment needs to be discussed with patients.”
The alert follows another piece of disappointing news, namely the failure of its SERVE-HF clinical trial. This would have helped treat patients who suffer from both sleep apnea and heart failure. The company’s shares fell after the news was announced as investors digested the possibility of weaker sales from not being able to explore this area of future growth.